secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akili, Inc. (—)
CIK:        0001850266
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001193125-23-233939
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akili shifts to non-prescription model, cuts workforce 40%, extends cash runway to 2H 2025
--------------------------------------------------------------------------------

- Workforce reduced ~40%; field sales and market access teams eliminated, representing ~2/3 of cuts. Severance cost estimated $2.3–2.8M.
- EndeavorOTC generated 125,971 first-time downloads, 4,170 active subscribers, $81.88 ARPU in first three months.
- 2023 non-GAAP total opex guidance $55–60M; 2024 non-GAAP opex $42–47M.
- Cash, cash equivalents, and short-term investments expected to fund operations into 2H 2025.
- Non-prescription model expected to achieve 60–70% gross margins by late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850266/000119312523233939/0001193125-23-233939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850266/000119312523233939/d554445d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-233939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer